LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

NCT06876675 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

167

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Hyperlipidemia

Interventions

DRUG: Lorlatinib

Sponsor

Peking University Third Hospital